Trends of second-line eradication therapy for helicobacter pylori in Japan: A multicenter study in the Tokyo metropolitan area

Helicobacter

Volumn 18, Issue 6, 2013, Pages 468-472

  Asaoka, Daisuke ^a   Nagahara, Akihito ^a   Matsuhisa, Takeshi ^b   Takahashi, Shin ichi ^c   Tokunaga, Kengo ^c   Kawai, Takashi ^d   Kawakami, Kohei ^d   Suzuki, Hidekazu ^e   Suzuki, Masayuki ^f   Nishizawa, Toshihiro ^f   Kurihara, Naoto ^g   Ito, Masayoshi ^h   Sasaki, Hitoshi ^a   Omata, Fumio ⁱ   Mizuno, Shigeaki ^j   Torii, Akira ^k   Ohkusa, Toshifumi ^l   Mine, Tetsuya ^m   Sakaki, Nobuhiro ⁿ  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^g Nerima General Hospital   (Japan)

^h Tokyo Hp Study Group   (Japan)

ⁱ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^j NIHON UNIVERSITY   (Japan)

^k Tokyo HP Study Group   (Japan)

^l JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Foundation for Detection of Early Gastric Carcinoma   (Japan)

more..

Author keywords

7 day triple therapy; Helicobacter pylori; Metonidazole; Proton pump inhibitor; Second line therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREND STUDY;

7-DAY TRIPLE THERAPY; HELICOBACTER PYLORI; METONIDAZOLE; PROTON PUMP INHIBITOR; SECOND-LINE THERAPY;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DISEASE ERADICATION; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; RETROSPECTIVE STUDIES; TOKYO; YOUNG ADULT;

EID: 84886280325     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12063     Document Type: Article

References (24)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
2. Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 2010;47:53-8.
3. Nagahara A, Miwa H, Kawabe M, et al. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J Gastroenterol 2004;39:1051-5.
4. Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M, Sato N. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16:613-8.
5. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
6. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY, Kwon DH. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-6.
7. Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 2005;11:307-11.
8. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-23.
9. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-10.
10. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 2004;39:927-30.
11. Murakami K, Okimoto T, Kodama M, Sato R, Miyajima H, Ono M, Inoue K, Watanabe K, Otsu S, Fujioka T. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Helicobacter 2006;11:436-40.
12. Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Jpn J Infect Dis 2006;59:367-9.
13. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T. A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori. Digestion 2007;76:215-20.
14. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008;42:139-42.
15. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010;15:21-7.
16. Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol 2013;47:233-8.
17. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001;15:1473-8.
18. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
19. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8.
20. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
21. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
22. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009;14:86-90.
23. Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011;16:234-40.
24. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009;14:29-35.